View Post

Alpha-TEA helps with breast cancer

In Clinical Trials by Barbara Jacoby

By: Christina Burkhart From: abc12.com One in eight women will be diagnosed with breast cancer at some point in her lifetime. One in four of those breast cancer diagnosis will be HER-2-positive. It’s an aggressive form of breast cancer and is more likely to recur than HER2-negative breast cancer. Now a new trial is underway to stop this cancer in …

View Post

GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers

In Clinical Trials by Barbara Jacoby

Source: GT Biopharma, Inc. From: prnewswire.com GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and international patent applications, and the initiation of clinical development of TriKE™ therapy for the treatment of HER2+, HER3+ and HER2+/HER3+ heterodimer …

View Post

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

In Clinical Trials by Barbara Jacoby

Source: Molecular Templates, Inc. From: globenewswire.com Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types  HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage …

View Post

Trastuzumab-Containing Regimens and Novel Drugs Mark the Precision Medicine Era of HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com Although HER2 positivity has been identified as a predictive factor of response to chemotherapy, it remains controversial considering that responses to chemotherapy can vary in patients with certain disease characteristics. The aggressiveness of early breast cancer and the overall prognosis of patients with the disease is highly dependent on the presence of aberrations in the …

View Post

HER2+ breast cancer patients live longer if drugs given before surgery eradicate tumour

In Clinical Trials by Barbara Jacoby

By: European Organisation for Research and Treatment of Cancer From: medicalxpress.com Final analysis of results from a randomised clinical trial of lapatinib and trastuzumab given before surgery in patients with early HER2-positive breast cancer has found that women who had no signs of residual disease after treatment (known as a pathological complete response, pCR) survived longer without the cancer returning …

View Post

Study finds link between beta-blockers and survival outcomes in some breast cancer patients

In Clinical Trials by Barbara Jacoby

Source: Flinders University From: news-medical.net New research led by Flinders University has found a link between beta-blockers and survival outcomes in some breast cancer patients. Beta-blockers, commonly used to manage cardiovascular disease, were negatively associated with survival outcomes in patients with HER2 (Human Epidermal Growth Factor Receptor 2) positive advanced breast cancer, according to a new paper in the Frontiers …

View Post

Updated ALTERNATIVE Results Favor Dual HER2 Blockade in HER2+/HR+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jared Kaltwasser From: targetedonc.com “Dual targeting of HER2-positive tumors with [trastuzumab] and [lapatinib] is beneficial because of differing mechanisms of action and because of the well-characterized synergistic interaction between them in HER2 [breast cancer] models.” Updated results from the phase 3 ALTERNATIVE study showed that dual HER2 blockade plus aromatase inhibition (AI) in post-menopausal women with HER2-positive, hormone receptor …

View Post

Interview: The Development of Sermonix’ Lasofoxifene in Advanced or Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Editorial Team From: oncozine.com In 2014 David Portman, MD, a leading clinical researcher and expert in women’s health, sexual medicine and menopause, and selective estrogen receptor modulators (SERM) founded Sermonix Pharmaceuticals, is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products. With a precision medicine focus for bringing targeted oncology products through development, …

View Post

Study: Significantly Shorter Drug Therapy Is Just as Effective for Some Breast Cancer Patients as Long-Term Options

In Clinical Trials by Barbara Jacoby

By: Jyoti Shelar From: forbes.com Scientists in India have found that women identified in the early stages of breast cancer can be treated with a short-term therapy that’s as effective as its longer-term alternative. The study’s clinical trials also show lower rates of cardiac toxic effects. One in five women suffering from breast cancer has a particularly aggressive, rapidly growing …

View Post

Honeybee Venom Kills Aggressive Breast Cancer Cells, Boosts Chemo Agents

In In The News by Barbara Jacoby

By: Michelle Taylor From: laboratoryequipment.com In 1950, Laszlo Havas published a study in Nature that showed bee venom reduced the growth of tumors in plants. Since then, the European honeybee (Apis mellifera) has been the source of a number of medicinal products used by humans, but the molecular underpinnings of bee venom are still poorly understood. Ciara Duffy’s latest research …